4th Quarter - Report

W STRATEGIES, LLC for ALEXION PHARMACEUTICALS

Firm
Client
Income
$60,000
Expenses
—

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Medicare/Medicaid MMM

Education about reimbursement for orphan drug therapies in skilled nursing facilities and proposed add-on payments in inpatient hospitals.

LobbyistCovered position, as disclosed
DARREN WILLCOX —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Taxation/Internal Revenue Code TAX

H.R.1/S.1: Tax Cuts and Jobs Act, as it relates to the Orphan Drug Tax Credit.

LobbyistCovered position, as disclosed
DARREN WILLCOX —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 1 (115th), S. 1 (115th)

Health Issues HCR

Education about the value of innovative new medicines and the Orphan Drug Act. H.R.3922: CHAMPIONING HEALTHY KIDS Act. H.R.4679: Ensuring Equal Access to Treatments Act of 2017. Education about the 340(b) program.

LobbyistCovered position, as disclosed
DARREN WILLCOX —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 3922 (115th), H.R. 4679 (115th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.